The Incidence and Prevalence of Systemic Lupus Erythematosus, 2002–2004: The Georgia Lupus Registry

Lim, S. Sam; Bayakly, A. Rana; Helmick, Charles G.; Gordon, Caroline; Easley, Kirk A.; Drenkard, Cristina

doi:10.1002/art.38239

Cited by 308 publications

(300 citation statements)

References 30 publications

Supporting

Mentioning

279

Contrasting

Unclassified

Order By: Relevance

“…Two recent population-based studies in the US estimated prevalence using surveillance methods for potential case identification and incorporating American College of Rheumatology (ACR) criteria and treating rheumatologist diagnosis in the validation process. The overall crude prevalence was 74.4 per 100,000 in Georgia's Fulton and Dekalb counties and 72.1 per 100,000 in southeastern Michigan when using the ACR definition (13,14).…”

Section: Discussionmentioning

confidence: 96%

Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?

Sjöwall

Rönnblom

Jönsen

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. Worldwide prevalence estimates of systemic lupus erythematosus (SLE) range from 3 to 207 per 100,000, depending on region and population, SLE definition, case sources, and other methodologic considerations. We aimed to determine the prevalence of SLE in Sweden on January 1, 2010, using population-based registers. Methods. Linking multiple national registers, we identified all possible inpatient and outpatient visits with SLE-specific discharge diagnoses and relevant prescription dispensations among living individuals registered in Sweden on January 1, 2010. SLE was defined from a lenient classification (requiring only a single visit) to stricter definitions that required multiple visits with a history of relevant specialist care and a dispensation for common SLE medications. Prevalence was calculated overall and by sex, age (0 -14 years, 15-49 years, and >50 years, as well as in 5-year age groups), and county of residence. Results. Overall prevalence ranged from 46 per 100,000 for the strictest definition to 85 per 100,000 for the least strict definition. As expected, SLE was more common among females (range 79 -144 per 100,000) than males (range 12-25 per 100,000) and varied by age. The up to 4-fold variation by county was unexpected. Prevalence generally increased with age (2, 52, and 95 per 100,000 by increasing age group, 0 -14 years, 15-49 years, and >50 years, respectively, using a moderately strict definition) and also varied by county. Conclusion. Variations of prevalence by age and sex were consistent with previous studies and overall ranged from 46 to 85 per 100,000. We observed a surprising geographic variation in the prevalence of SLE in Sweden on

show abstract

Section: Discussionmentioning

confidence: 96%

Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?

Sjöwall

Rönnblom

Jönsen

et al. 2014

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…According to 2 populationbased registries, its age-adjusted prevalence is 73 cases per 100,000 persons, and its incidence is 5.5 cases per 100,000 person-years in the US (2,3). The majority of cases occur in women of child-bearing age (1).…”

Section: Introductionmentioning

confidence: 99%

Glucocorticoid Use in Patients With Systemic Lupus Erythematosus: Association Between Dose and Health Care Utilization and Costs

Chen

Choi

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To investigate the determinants of health care utilization and costs with use of glucocorticoid (GC) drugs among adult systemic lupus erythematosus (SLE) patients. Methods. This cross-sectional study analyzed established SLE patients identified by International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes from a large US insurance claims database in 2007-2011. Five patient groups were defined by their oral GC use during a 1-year period: non-GC users, <60 days of GC use, and ‡60 days of GC use in low dosage (£7.5 mg/day), medium dosage (>7.5 to £15 mg/day), or higher dosage (>15 mg/day). Annual health care utilization and costs were compared across these groups. Incremental costs of GC groups, calculated as the difference in total health care costs compared with those of the non-GC group, were estimated from multivariable regressions adjusting for demographic/clinical characteristics and stratified by concomitant immunosuppressant use. Results. A total of 50,230 SLE patients were identified (52% non-GC users, 20% <60 days of GC use, and 10% low dose, 10% medium dose, and 8% higher dose of ‡60 days of GC use). GC users had higher health care utilization and costs. Incremental costs were significant (all P < 0.01) for medium-dose ($5,319 and $6,913) and higher-dose ($12,517 and $15,019) GC groups, regardless of concomitant immunosuppressant use. The incremental costs for the low-dose GC group with concomitant immunosuppressants ($1,285; P 5 0.04) were smaller than the incremental costs for the low-dose GC group without concomitant immunosuppressants ($2,514; P < 0.01). Conclusion. GC use, especially at higher doses, was associated with higher health care utilization and costs. Findings in users with concomitant immunosuppressants suggest that therapies with a GC-sparing effect may be associated with lower economic burden in SLE treatment.

show abstract

“…Many studies (epidemiological) have found that Caucasians have a twofold to threefold lower incidence and prevalence rates than Asians [72][73][74][75][76][77][78][79]. Moreover, it was found in many studies that Asians had more severe symptoms and signs of the disease, more aggressive kidney involvements, and the autoantibody positivity was also higher in Asians than in non-Asians [76,[79][80][81][82][83].…”

Section: Incidence and Prevalence Of Slementioning

confidence: 99%

Introduction and Physiology of Lupus

Zaman¹

2017

Lupus

View full text Add to dashboard Cite

The Incidence and Prevalence of Systemic Lupus Erythematosus, 2002–2004: The Georgia Lupus Registry

Cited by 308 publications

References 30 publications

Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?

Systemic Lupus Erythematosus Prevalence in Sweden in 2010: What Do National Registers Say?

Glucocorticoid Use in Patients With Systemic Lupus Erythematosus: Association Between Dose and Health Care Utilization and Costs

Introduction and Physiology of Lupus

Contact Info

Product

Resources

About